Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Neofollics lotion is discussed as a hair loss treatment, but users report it is ineffective and not supported by strong evidence. Users suggest sticking to FDA-approved treatments like Minoxidil and Finasteride.

Ketoconazole shampoo does not significantly reduce systemic or scalp DHT levels and is mainly used for its anti-fungal and anti-inflammatory effects. It is not a replacement for finasteride, which is recommended by some users despite concerns about side effects.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

The conversation discusses challenges in obtaining finasteride in the Netherlands and explores alternatives like natural DHT blockers and topical finasteride. Suggestions include consulting different doctors or dermatologists and considering cost-effective options like cutting higher-dose tablets.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

User discusses a topical hair solution containing Tretinoin, Dutasteride, and Ketoconazole, and asks if it's safe to combine and leave in hair. Concerns include Ketoconazole being left in hair and Tretinoin's effects with Dutasteride and Ketoconazole.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.

A British man's death at a Turkish hair transplant clinic raised safety concerns about such clinics. Users discussed risks of cheaper clinics and suggested alternatives like Thailand, Korea, and Colombia.

Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.

A 22-year-old man has been using topical melatonin for a year to slow hair loss and it appears to be effective. He's seeking alternatives to finasteride due to potential side effects, and is interested in understanding how melatonin works to prevent hair shedding.

The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

A user experienced decreased free testosterone levels after three months of using finasteride, despite positive results in hair shedding reduction. They are considering switching to topical finasteride and plan to conduct further blood tests, including checking SHBG levels, to understand the hormonal changes.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

Intense microneedling with heavy pressure and bleeding did not improve hair growth after 4 months. The user advises against this method, noting no benefits and potential harm, and mentions using minoxidil without success.

The user believes neck tension and poor posture contribute to hair loss, noticing improvements with yoga and muscle relaxation. Replies suggest androgenic alopecia as the cause and recommend exercises.

The user has been using a combination of 0.3% topical finasteride, minoxidil, ketoconazole, and microneedling once a week for two months with positive results and no side effects. They apply the treatment daily using a spray and have short hair, which makes application easier.